Shoreline Biosciences CEO Kleanthis Xanthopoulos, Ph.D. joins the Business of Biotech to share the company’s strategy for the development, manufacture, and commercialization of off-the-shelf NK (natural killer) cell therapy. On this episode, Dr. Xanthopoulos shares why the cell and gene immunotherapeutic market has underperformed to date, why he believes autologous is not the long-term path forward, and the […]

Musculoskeletal care is a big problem for the U.S. healthcare system, digital health companies say. Disorders are common and expensive to treat, but care that could cut down those high costs is inaccessible to many who need it. That message is resonating with investors. Over the past year, they’ve poured hundreds of millions of dollars into the […]

Cannabis is a developing industry in California, and the intricacies and various effects of the growing industry span from the development of proper legislation and best practices with social equity to a lack of understanding of the product.  A rally in front of the state Capitol building in Sacramento on Jan. 13 brought cannabis farmers […]